Fungicidal Activity of Fluconazole against Candida albicans in a Synthetic Vagina-Simulative Medium

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 161-167

  Moosa, Mahomed Yunus S ^a   Sobel, Jack D ^a   Elhalis, Hussain ^a   Du, Wenjin ^a   Akins, Robert A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CARBOXYLIC ACID; FLUCONAZOLE; GLYOXYLIC ACID; MALONIC ACID;

ANALYSIS; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CELL VIABILITY; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; IN VITRO STUDY; MICROENVIRONMENT; NONHUMAN; PH; PRIORITY JOURNAL; SIMULATION; SPECIES; STANDARD; SYNTHESIS; VAGINA;

ACETIC ACID; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CULTURE MEDIA; FEMALE; FLUCONAZOLE; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; VAGINA;

EID: 0347361710     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.161-167.2004     Document Type: Article

References (53)

1. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389. (Erratum, 170:1641.)
2. Arikan, S., M. Akova, M. Hayran, O. Ozdemir, M. Erman, D. Gur, and S. Unal. 1998. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin. Infect. Dis. 26:903-908.
3. Arneborg, N., L. Jespersen, and M. Jakobsen. 2000. Individual cells of Saccharomyces cerevisiae and Zygosaccharomyces bailii exhibit different short-term intracellular pH responses to acetic acid. Arch. Microbiol. 174:125-128.
4. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.
5. Bard, M., N. D. Lees, T. Turi, D. Craft, L. Cofrin, R. Barbuch, C. Koegel, and J. C. Loper. 1993. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28:963-967.
6. Beck-Sague, C. M., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
7. Beggs, W. H., and C. E. Hughes. 1986. Role of pH in the lethal direct cell damaging action of miconazole. Res. Commun. Chem. Pathol. Pharmacol. 53:407-410.
8. Casal, M., H. Cardoso, and C. Leao. 1998. Effects of ethanol and other alkanols on transport of acetic acid in Saccharomyces cerevisiae. Appl. Environ. Microbiol. 64:665-668.
9. Casal, M., H. Cardoso, and C. Leao. 1996. Mechanisms regulating the transport of acetic acid in Saccharomyces cerevisiae. Microbiology 142:1385-1390.
10. Clemons, K. V., and D. A. Stevens. 2000. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med. Mycol. 38:213-219.
11. Dannaoui, E., V. Lacoste, C. Prat, and M. A. Piens. 1997. Fluconazole susceptibility of Candida isolates from oropharyngeal candidosis. Mycoses 40:279-282.
12. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: three-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40:1298-1302.
13. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511.
14. Garcha, U. K., E. Brummer, and D. A. Stevens. 1995. Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. Mycopathologia 132:123-128.
15. Garcia, M. T., F. Minguez, M. T. Llorente, and J. Prieto. 2000. Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations on the of 4 antifungal agents on previously treated Candida spp. Scand. J. Infect. Dis. 32:669-673.
16. Goihman-Yahr, M., L. Pine, M. C. Albornoz, L. Yarzabal, M. H. de Gomez, B. San Martin, A. Ocanto, T. Molina, and J. Convit. 1980. Studies on plating efficiency and estimation of viability of suspensions of Paracoccidioides brasiliensis yeast cells. Mycopathologia 71:73-83.
17. Gujral, S., E. Brummer, and D. A. Stevens. 1996. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J. Infect. Dis. 174:888-890.
18. Guldfeldt, L. U., and N. Arneborg. 1998. Measurement of the effects of acetic acid and extracellular pH on intracellular pH of nonfermenting, individual Saccharomyces cerevisiae cells by fluorescence microscopy. Appl. Environ. Microbiol. 64:530-534.
19. Kelly, S. L., D. C. Lamb, A. J. Corran, B. C. Baldwin, and D. E. Kelly. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem. Biophys. Res. Commun. 207:910-915.
20. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett. 400:80-82.
21. Kontoyiannis, D. P. 2000. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae. J. Antimicrob. Chemother. 46:191-197.
22. Krcmery, V., M. Huttova, F. Mateicka, L. Laho, L. Jurga, A. Ondrusova, Z. Tarekova, K. Kralinsky, J. Hanzen, A. Liskova, M. Mrazova, A. Sabo, M. Pisarcikova, G. Kovacicova, D. Chovancova, and Z. Szovenyiova. 2001. Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J. Antimicrob. Chemother. 48:521-525.
23. Ludovico, P., F. Rodrigues, A. Almeida, M. T. Silva, A. Barrientos, and M. Corte-Real. 2002. Cytochrome c release and mitochondria involvement in programmed cell death induced by acetic acid in Saccharomyces cerevisiae. Mol. Biol. Cell 13:2598-2606.
24. Ludovico, P., M. J. Sousa, M. T. Silva, C. Leao, and M. Corte-Real. 2001. Saccharomyces cerevisiae commits to a programmed cell death process in response to acetic acid. Microbiology 147:2409-2415.
25. Marr, K. A., T. R. Rustad, J. H. Rex, and T. C. White. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43:1383-1386.
26. McIntyre, K. A., and J. N. Galgiani. 1989. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob. Agents Chemother. 33:1095-1100.
27. Meis, J., M. Petrou, J. Bille, D. Ellis, D. Gibbs, et al. 2000. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Ugeskr. Laeger. 162:1907-1908.
28. Mian, U. K., M. Mayers, Y. Garg, Q. F. Liu, G. Newcomer, C. Madu, W. Liu, A. Louie, and M. H. Miller. 1998. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J. Ocul. Pharmacol. Ther. 14:459-471.
29. Natarajan, U., N. Randhawa, E. Brummer, and D. A. Stevens. 1998. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J. Med. Microbiol. 47:359-363.
30. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
31. Onyewu, C., J. R. Blankenship, M. Del Poeta, and J. Heitman. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964.
32. Owen, D. H., and D. F. Katz. 1999. A vaginal fluid simulant. Contraception 59:91-95.
33. Peng, T., and J. N. Galgiani. 1993. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 37:2126-2131.
34. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, and S. A. Messer. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-3259.
35. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1999. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222.
36. Prudencio, C., F. Sansonetty, and M. Corte-Real. 1998. Flow cytometric assessment of cell structural and functional changes induced by acetic acid in the yeasts Zygosaccharomyces bailii and Saccharomyces cerevisiae. Cytometry 31:307-313.
37. Rex, J. H., T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards. 2000. Practice guidelines for the treatment of candidiasis, Infectious Diseases Society of America. J. Parenter. Enteral Nutr. 24:119-125.
38. Richardson, K., K. Cooper, M. S. Marriott, M. H. Tarbit, P. F. Troke, and P. J. Whittle. 1990. Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. 12:S267-S271.
39. Ruhnke, M., A. Eigler, E. Engelmann, B. Geiseler, and M. Trautmann. 1994. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22:132-136.
40. Shimokawa, O., and H. Nakayama. 1999. Acetate-mediated growth inhibition in sterol 14α-demethylation-deficient cells of Candida albicans. Antimicrob. Agents Chemother. 43:100-105.
41. Shimokawa, O., and H. Nakayama. 2000. Estimation of minimum sterol 14α-demethylation-inhibitory concentration of azoles in Candida yeasts using acetate-mediated growth inhibition: potential utility in susceptibility testing. J. Clin. Microbiol. 38:2893-2896.
42. Sobel, J. D. 1999. Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resist. Update 2:148-152.
43. Sobel, J. D. 2002. Treatment of vaginal Candida infections. Expert Opin. Pharmacother. 3:1059-1065.
44. Sobel, J. D., P. S. Kapernick, M. Zervos, B. D. Reed, T. Hooton, D. Soper, P. Nyirjesy, M. W. Heine, J. Willems, H. Panzer, and H. Wittes. 2001. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am. J. Obstet. Gynecol. 185:363-369.
45. Sobel, J. D., M. Zervos, B. D. Reed, T. Hooton, D. Soper, P. Nyirjesy, M. W. Heine, J. Willems, and H. Panzer. 2003. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob. Agents Chemother. 47:34-38.
46. Sohnle, P. G., B. L. Hahn, and M. D. Erdmann. 1996. Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob. Agents Chemother. 40:2622-2625.
47. Sohnle, P. G., B. L. Hahn, T. A. Fassel, and V. M. Kushnaryov. 1998. Analysis of fluconazole effect on Candida albicans viability during extended incubations. Med. Mycol. 36:29-36.
48. Troillet, N., C. Durussel, J. Bille, M. P. Glauser, and J. P. Chave. 1993. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 12:911-915.
49. Troke, P. F., R. J. Andrews, K. W. Brammer, M. S. Marriott, and K. Richardson. 1985. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob. Agents Chemother. 28:815-818.
50. Tullio, V., A. M. Cuffini, C. De Leo, F. Perrone, and N. A. Carlone. 1996. Interaction of Candida albicans, macrophages and fluconazole: in vitro and ex vivo observations. J. Chemother. 8:438-444.
51. Walsh, T. J., C. E. Gonzalez, S. Piscitelli, J. D. Bacher, J. Peter, R. Torres, D. Shetti, V. Katsov, K. Kligys, and C. A. Lyman. 2000. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J. Clin. Microbiol. 38:2369-2373.
52. Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.
53. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.